News | October 16, 2025
Merck KGaA to acquire chromatography business of JSR Life Sciences
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
The new plant will manufacture high-quality Type I borosilicate glass tubing
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
